EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression

Yuan Guo¹, Yan-Rong Zhao¹, Huan Liu², Yang Xin¹, Jian-Zhi Yu¹, Yun-Jin Zang¹* and Qing-guo Xu²,3*

Abstract

**Background:** Hepatocellular carcinoma (HCC), the second leading cause of cancer death worldwide, alone accounts for over half (466,100) of new cancer cases and 422,100 deaths based on the average year incidence rates of 2009 to 2011 in China. Due to unclear and complex underlying mechanisms for HCC development, effective therapy for HCC is still unavailable. The Wnt–β-catenin pathway is a critical contributor of HCC pathogenesis: 40–70% of HCCs from patients harbor the nuclear accumulation of β-catenin protein. However, the mechanisms for β-catenin activation are not fully understood.

**Methods:** The deletion of EHMT2 in Hep3B and Huh1 cells was achieved by transiently transfecting cells with pX459 plasmids, which carry EHMT2 specific small guide RNA (sgRNA) sequences for Cas9 protein. All experiments were performed in triplicate and repeated more than three times.

**Results:** In the present study, we observed that EHMT2 (but not EHMT1) mRNA and protein levels were significantly elevated in HCC compared with normal controls. Next, the results of Ki67 staining, as well as MTT, soft-agar and xenograft assays, in wild-type and EHMT2−/− Hep3B and Huh1 cancer stem cells collectively revealed that the elevation of EHMT2 expression is required for the tumorigenesis of HCC. Meanwhile, we found that elevated EHMT2 expression contributes to the activation of Wnt–β-catenin signaling: deletion of EHMT2 in Hep3B or Huh1 cells promoted the cytoplasmic localization of β-catenin and restrained the expression of Wnt–β-catenin signaling targets such as Myc, CCND1, MMP-7, etc. We demonstrated that EMHT2 directly mediates the H3K9me2 methylation of the APC promoter to epigenetically silence its expression. More intriguingly, our findings also showed that UNC0642, a specific inhibitor of EHMT2, exhibits anti-tumorigenesis effects in HCC both in vitro and in vivo, which were largely abolished by deletion of EHMT2 or overexpression of APC in Hep3B and Huh1 cells.

**Conclusion:** Altogether, our observations emphasize that the EHMT2–APC axis is a critical contributor to Wnt–β-catenin pathway activation in HCC, and UNC0642 may be a potential candidate for target drug treatment of HCC.

**Keywords:** Hepatocellular carcinoma, EHMT2, Wnt–β-catenin pathway, APC, UNC0642

Introduction

Hepatocellular carcinoma (HCC), the second leading cause of cancer death worldwide, alone accounts for over half (466,100) of the new cases and 422,100 deaths in recent years in China [1, 2]. Currently, risk factors including hepatitis B or C viral infections, alcohol-related cirrhosis, and non-alcoholic steatohepatitis have been frequently reported to mainly cause HCC [3–5]. In
China, due to the difficulties in early diagnosis, HCC also has the poorest survival with an age-standardized 5-year relative survival of only 10.1% [6, 7]. Moreover, HCC is a heterogeneous disease with highly heterogeneous risk factors, environmental or genetic susceptibilities, morphological diversity, signaling network disorders, and microenvironmental discrepancies, which largely limit the prediction of disease progress, molecular classification, and targeted therapy [8, 9]. However, the underlying mechanisms for HCC development are still exclusive. In treatment, only sorafenib, an anti-angiogenic and MAP kinase inhibitor, has been shown to improve the prognosis outcome of HCC patients [10]. To date, although multiple clinical trials with agents targeting FGFR2, VEGF, PDGF, EGF, IGF, mTOR, and TGFβ signaling pathways have been carried out, the effective therapy for HCC is still unavailable.

The Wnt–β-catenin pathway is a key molecular mechanism that involves the processes of embryonic development and tissue homeostasis [11, 12]. In rest status, β-catenin (encoded by gene CTNNB1) exposes its armadillo domain repeats to bind its interactors including Axin1 and APC (adenomatous polyposis coli protein) as well as GSK3β for the cytoplasmic arrest and ubiquitination-mediated degradation by the proteasome [13]. When a Wnt ligand (such as Wnt3a) binds to a Frizzled (FZD) receptor, a seven-transmembrane domain protein at the cell membrane, the cytoplasmic sequestered β-catenin is released and translocates into the nucleus to interact with transcriptional factors of the TCF/LEF family to promote the expression of Wnt–β-catenin signaling targets including Myc, CCND1, MMP-7, etc. [11, 14, 15]. In the pathogenesis of HCC, the Wnt–β-catenin pathway is a critical contributor, evidenced by 40–70% of HCCs harbor nuclear accumulation of the β-catenin protein [14, 16, 17]. Specifically, activation of β-catenin during hepatocarcinogenesis is mainly mediated by CTNNB1 gene mutation (in 8–30% tumors) or loss-of-function mutation of APC (in 1–3%)/AXIN1 (in 8–15%) [18–20]. However, in some special cases without mutations of CTNNB1, APC, and AXIN1, the mechanisms of how the β-catenin in HCC is activated are not fully understood.

EHMT2 (also known as G9a), a nuclear histone lysine methyltransferase, specifically mono- and di-methylates lysine-9 of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin [21, 22]. Generally, H3K9me in gene promoters epigenetically mediates gene transcription repression by recruiting heterochromatin components such as heterochromatin protein 1 (HP1) to the methylated histones [23]. Over the past decades, EHMT2 has been demonstrated to display fundamental functions in embryogenesis in genetic mouse models, for example, deletion of EHMT2 in mice resulted in embryonic lethality [24, 25]. Recently, the roles of EHMT2 in cancers have been extensively explored by different groups. Overexpression of EHMT2 has been observed in various cancers including esophageal squamous cell carcinoma, aggressive lung cancer, multiple myeloma, brain cancer, ovarian carcinoma, etc. [26–28]. More importantly, the high EHMT2 expression was shown to be associated with poor outcomes of patients’ survival [28–30]. The elevated EHMT2 expression level is commonly correlated with higher methylation levels and suppression of important tumor suppressor genes expression, suggesting that the alteration is functional. In 2018, Zhang et al. reported that EHMT2 is upregulated in non-small cell lung cancer (NSCLC) to epigenetically restore APC2 functions and then silences the Wnt–β-catenin pathway [23]. In this study, we aimed to investigate the roles of EHMT2 in the pathogenesis of hepatocellular carcinomas and identify the underlying mechanisms.

Methods and materials

Patient specimens

In the present study, tumor and adjacent normal tissues were collected from 33 patients with liver hepatocellular carcinoma who were enrolled in the Affiliated Hospital of Qingdao University from Sept 2016 to Oct 2018. All the related pathological sections were identified by three independent oncologists. The fresh specimens were quickly frozen in liquid nitrogen for protein extraction and immersed into RNA Later™ Stabilization Solution (Cat: AM7020, ThermoFisher Scientific, Waltham, USA) for RNA extraction. The written informed consent forms were obtained from the patients or their families. All the protocols involved in our experiments were approved by the Ethics Committee of Qingdao University and study methodologies conformed to the standards set by the Declaration of Helsinki.

Cell culture

Hep3B cells (Cat: HB-8064) were purchased from American Type Culture Collection (ATCC, Manassas, USA). Hep3B cells were cultured in ATCC-formulated Eagle’s Minimum Essential Medium (Cat: 30-2003, Manassas, USA) plus 10% fetal bovine serum (FBS, Gibco, Rockville, USA) and 50 μg/ml penicillin/ streptomycin (P/S, Gibco, Rockville, USA). Huh1 (Cat: JCRB0199) cells were purchased from the Japanese Collection of Research Resources Cell Bank (JCRB, Osaka, Japan), and were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Rockville, USA) plus 10% FBS and 50 μg/ml P/S. Cells were maintained in an incubator at 37 °C with 5% CO2. For transient transfection, PolyJet reagent (SL100688, Signagen, USA) was used following the manufacturer’s instructions.
Construction of KO cell lines
The deletion of EHMT2 in Hep3B/Huh1 cells was achieved by transiently transfecting cells with pX459 plasmids, which carry EHMT2 specific small guide RNA (sgRNA) sequences for Cas9 protein. The plasmids were generated by directly ligating synthesized oligos with linearized pX459 vector by BbsI restriction enzyme (Cat: R0539V, New England Biolabs, Ipswich, USA). Three independent sgRNAs were designed based on NGS protospacer adjacent motif (PAM) sequences (https://zlab.bio/guide-design-resources). The related sgRNA sequences are listed as follows: KO-sgACSM3#1: 5′-CCT CTG GCC TCC TTG GCC CG-3′; KO-sgACSM3#2: 5′-CGT GGC TCC TTG GCC CGC GG-3′; KO-sgACSM3#3: 5′-CAA GGA GCC ACG AGG TGA GG-3′. After 36 h of transfection, the cells were selected using puromycin at a dose of 1.0 μg/ml (Cat: A1113803, ThermoFisher Scientific, Waltham, MA USA) for 1–2 days. When cells recovered from anti-biotin selection, the single-cell clones were sorted using a flow cytometer. About 30 days later, the grown-up single clones were picked up and were subjected to sequencing and Western blot identification.

RNA extraction and real-time quantitative PCR RT-qPCR
Tissue or cell mRNAs were extracted using TaKaRa MiBEST Universal RNA Extraction Kit (Cat: 9767, Tokyo, Japan) following the manufacturer’s instructions. cDNAs were synthesized using PrimeScript™ RT Master Mix (Cat: RR036B, Takara, Tokyo, Japan). The specific mRNAs were quantified by RT-qPCR using TB Green Fast qPCR Mix (Cat: RR430B, Takara, Tokyo, Japan) on the Thermal Cycler Dice Real-Time System III (Code No. TP950, Takara, Tokyo, Japan). The EHMT2 levels were calculated by the 2−ΔΔCT method with ACTB mRNA as the internal control. The oligos used for RT-qPCR were listed as follows. EHMT2: forward, 5′-TCC AAT GAC ACA TCT TCG CTG-3′; reverse, 5′-CTG ATG CGG TCA ATC TTG GG-3′. ACTB: forward, 5′-CAT GTA CGT TGC TAT CCA GGC-3′; reverse, 5′-CTC CTT AAT GTC ACGCACGAT-3′. Myc: forward, 5′-GTC AAG AGG CGA ACA CAC AAC-3′; reverse, 5′-TTG GAC GGA CAG GAT GTA TGC-3′. CND1: forward, 5′-CGA TGG GCC CGC AGC ATT TC-3′; reverse, 5′-CAT GGA GGG CGG ATT GGA A-3′. MMP-7: forward, 5′-ATG TGG AGT GCC AGA TGG TGC-3′; reverse, 5′-AGC AGT TCC CCA TAC AAC TTT C-3′.

Western blot
Specifically, for the Western blot of nuclear proteins, the nuclei of cells were isolated using Nucleoprotein Extraction Kit (Cat: C500009, Sangon Biotech, Shanghai, China). After quantified with Pierce™ BCA Protein Assay Kit (Cat: 23225, ThermoFisher Scientific, Waltham, MA USA), equal protein samples were resolved in 10% SDS-PAGE gel. Then, the separated proteins were transferred onto nitrocellulose filter (NC) membrane. After blocked in 5% non-fat milk/PBS for 1 h at room temperature, the membranes were washed with TBST for 3 × 5 min and then incubated with primary antibody at 4°C overnight. The next day, the membranes were washed with TBST for 3 × 5 min at room temperature, and then were probed with the HRP (peroxidase)-conjugated secondary antibody at room temperature for 1 h. Signals were detected using Pierce ECL Western Blotting Substrate (Cat: 32106, ThermoFisher Scientific, Waltham, MA USA) on Tanon 5200 multi-automatic image analysis system (Tanon, Shanghai, China). The protein bands were quantified using ImageJ software. Primary antibodies of EHMT2 (Cat: #3306), β-Actin (Cat; #3700), β-catenin (Cat: #8480) were purchased from Cell Signaling Technology (Danvers, USA). H3K9me2 (Cat: 49-1007) was purchased from ThermoFisher Scientific (Waltham, MA USA).

Immunofluorescence staining
Hep3B and Huh1 cells were seeded onto Poly-lysine (P4707, Millipore Sigma, Darmstadt, Germany) coated cover glasses. 1–2 days later, cells were washed with PBS three times at room temperature and then fixed with 4% paraformaldehyde Fix Solution (Cat: E672002, Sangon, Shanghai, China) for 15 min. Next, the fixed cells were permeabilized with 0.2% Triton X-100 (Cat: E-IR-R122, Elabscience Biotechnology, Wuhan, China) for 10 min at room temperature. Sections were incubated with Ki67 (Cat: 27,309–1-AP, Proteintech, Rosemont, USA) or β-catenin (Cat: #8480, CST) primary antibodies at 4°C overnight. The next day, sections were washed using PBS for 3 × 5 min at room temperature, and then incubated with 4,6-diamidino-2-phenylindole (DAPI) dye (Cat: D1306, ThermoFisher Scientific, Waltham, MA, USA) and fluorophore-conjugated secondary antibodies at room temperature for 2 h. Images were captured by the Leica microscope.

Cell proliferation determination
Cell proliferation was determined by the MTT (Methylthiazolyldiphenyl-tetrazolium bromide) assays. MTT assay, based on the conversion of water-soluble MTT compound to an insoluble formazan product, was performed using a kit from Abcam (Cat: ab211091, Cambridge, USA) under the manufacturer’s instruction. Briefly, 1.0 × 10⁴ cells were seeded onto 96-well plates at the indicated points including 0, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 days. Next, the culture medium was replaced
with serum-free media and MTT reagent (10 μl) when the cells of the final round seeding totally spread on the plates. After a 3-h incubation at 37 °C, MTT solvent was added to incubate for 15 min, and then all the plates were briefly mixed to ensure homogeneous distribution of color. Finally, the absorbance was measured at a 590 nm wave using a Synergy HTX microplate reader (BioTek, Beijing, China).

**Colony formation assay**

The soft agar experiment was carried out as previously described [31]. Briefly, 1.0% agar and 2× related medium were evenly mixed at about 42°C, and then cold to make the 0.5% base layer. Cells (1.0 × 10⁵) were thoroughly mixed with 0.35% top layer agar. After the top agar solid, the plates were placed in a 37 °C incubator for 3 weeks. Finally, the colony formation was determined by crystal violet staining.

**Xenograft assay**

To determine the tumorigenesis of cells, Hep3B or Huh-1 cell lines were subjected to xenograft assay as previously described [32]. The nude mice BALB/c (n = 6 for each group) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). Cells (3.0 × 10⁶, in 150 μl sterile PBS) were subcutaneously injected into both sides of the animals. If necessary, the animals were treated with UNC0642 at 5 mg/kg via intraperitoneal injection with an interval of 3 days. Tumor volumes were recorded every 5 days by vernier caliper for 1 month.

**TCGA database analysis**

Expression profile data of liver hepatocellular carcinoma (LIHC) from TCGA (tumor tissues, n = 369; normal tissues, n = 50) and GTEx (normal tissues, n = 160) database were analyzed by GEPIA online tool (http://gepia2.cancer-pku.cn/). The expression pattern of EHMT1/2 was analyzed using a GTEx RNAseq datasheet for normal human tissues. The TPM was normalized and presented in log2-transformed values. In overall and disease-free survival analysis, GEPIA online tools were used, and the medium of EHMT2 expression was used as a cutoff.

**Statistical analysis**

All results were presented as mean ± SD, of which the duplication was specified in the related figure legends. GraphPad Prism 7 software (San Diego, USA) was used for statistical analysis. For two-group comparison, student’s or paired t-test was used; for three or multiple group comparison, one- or two-way ANOVA was used, followed by post hoc Bonferroni multiple comparisons. A p < 0.05 was considered as statistical significance.

**Results**

**High EHMT2 expression is unfavorable for patients with HCC**

To explore the roles of EHMT2 in HCC, we analyzed its expression level using the public data from TCGA and GTEx databases. Intriguingly, our results showed that the mRNA level of EHMT2 in HCC elevated significantly when compared with the normal controls from TCGA and GTEx (Fig. 1A). Consistently, these findings were confirmed by the expression data of clinical samples that we collected, indicated by EHMT2 expression both in mRNA and protein levels were dramatically increased in liver tumors when compared with the paired adjacent normal tissues (Fig. 1B, C). These observations imply EHMT2 expression level may exhibit clinical significance. To this end, we used the median of the EHMT2 mRNA level as the cutoff value to carry out overall (OS) and disease-free survival (DFS) analysis with GEPIA online tools. Interestingly, we observed that high EHMT2 expression predicted poor prognosis outcomes for patients with HCC both in OS (hazard ratio, HR = 1.9,

![Fig. 1](See figure on next page.)

**A** EHMT2 expression (mRNA) level in liver hepatocellular carcinoma (LHHC). Data from TCGA (tumor tissues, n = 369; normal tissues, n = 50) and GTEx (normal tissues, n = 160) database were analyzed by GEPIA online tool. TPM, transcripts per million reads. Line, medium; box, interquartile range (IQR); whiskers, non-outlier range; *p < 0.01. **B** mRNA level of EHMT2 in human specimens was determined by RT-qPCR. n = 31, ***p < 0.001 by paired t-test. **C** the protein level of EHMT2 in human specimens was determined by Western blot. The bottom section shows the representative of Western blot results. Samples are the same as 1B. NC, adjacent normal controls; Tu, tumors. n = 31, **p < 0.01 by paired t-test. **D** EHMT2-based overall and disease-free survival analysis of patients with HCC. In OS and DFS analysis, EHMT2 expression data from TCGA were used, and the median of EHMT2 expression served as the cutoff. High EHMT2 expression level more than median; Low EHMT2, expression level less than the median. A log-rank test was used for the hypothesis test. OS, overall survival analysis; DFS, disease-free survival analysis.
expression Chaisaingmongkol et al. [33], high (Fig. 1D). In 3 different molecular subtypes proposed by (GTEx, n=160)

$p=0.00057$) and DFS (HR = 1.5, $p=0.0076$) analysis (Fig. 1D). In 3 different molecular subtypes proposed by Chaisaingmongkol et al. [33], high EHMT2 expression also exhibited unfavorable effects for prognosis outcome in OS analysis, especially in the iClust2/3 subtype (with a high HR > 2.7) (Additional file 1: Figure S1A). However, in
DFS analysis based on EHMT2 expression, no significant difference in prognosis outcome was observed in subtype iClust1/2 (Additional file 1: Figure S1B). In the iClust3 subtype, the survival percentage of the high-EHMT2 group was significantly lower than the low-EHMT2 group with an HR = 2.8 ($p = 0.0043$) in DFS analysis, showing a similar effect on OS of patients (Additional file 1: Figure S1B). Altogether, our data showed that the expression of EHMT2 is elevated in HCC, which also indicates a poor clinical outcome.

**EHMT2 is required for the tumorigenesis of HCC**

EHMT2, as an epigenetic “writer” (a lysine methyltransferase), catalyzes mono- and di-methylation of histone H3 lysine 9 (H3K9me1/2) and non-histone proteins, which has been demonstrated to implicate a variety of human diseases [34]. Therefore, we speculated that EHMT2 plays some roles in tumorigenesis of HCC. To this end, we constructed several EHMT2 gene knockout cell lines in Hep3B and Huh1 using CRISPR/Cas9 technology. After Western blot identification, we obtained EHMT2 double-deletion (EHMT2$^{−/−}$) Hep3B and Huh1 single clones (Fig. 2A). In immunofluorescence staining of Ki67, the Ki67 positive percentage was slightly but significantly decreased in EHMT2$^{−/−}$ Hep3B and Huh1 cells (Fig. 2B). These data indicate EHMT2 possesses a proliferation-enhancing function in HCC cells. Similarly, our MTT assay (determining cell proliferation) result also displayed that wild-type Hep3B and Huh1 grew significantly faster than EHMT2$^{−/−}$ ones since 1.0–1.5 days of seeding cells (Fig. 2C). Furthermore, we found the deletion of EHMT2 effectively abated the anchorage-independent growth both in Hep3B and Huh1 cells, as shown in the decrease of colony size of EHMT2$^{−/−}$ groups compared with wild type groups (Fig. 2D). These observations altogether demonstrate that EHMT2 possesses tumor-promoting function in HCC cells in vitro. Besides, we estimated EHMT2’s tumor-promoting function in vivo using xenograft assay. In the xenograft assay, we observed that deletion of EHMT2 in Hep3B and Huh1 led to tumor growth suppression (Additional file 1: Figure S2A). Consistently, our finding showed that, compared with wild-type cells, the final tumor weights of EHMT2$^{−/−}$ Hep3B and Huh1 cells significantly reduced (Fig. 2E). These findings indicate that EHMT2 also promotes tumor growth in vivo. Taken together, the elevation of EHMT2 expression is required for HCC tumorigenesis.

**EHMT2 inhibitor exhibits anti-tumorigenesis effects in HCC**

UNC0642, a well-known EHMT1/2 selective inhibitor, has been widely reported to inhibit the growth of multiple kinds of cancer cells including neuroblastoma, melanoma, bladder cancer, non-small cell lung cancer, etc. [31, 35–37]. However, whether UNC0642 is effective in HCCs is still exclusive. In our experiment, we also found that UNC0642 remarkably suppressed the enzymatic activity of EHMT2 without influencing its protein level, indicated by the reduction of H3K9me2 protein level after UNC0642 treatment in Hep3B and Huh1 cells (1.0 μM for 48 h) (Fig. 3A). In wild-type Hep3B and Huh1 cells, UNC0642 treatment dramatically decreased the percentage of Ki67 positive cells, which was significantly blocked by the deletion of EHTM2 (Fig. 3B). Consistently, cell growth also was effectively suppressed by UNC0642 treatment on wild-type Hep3B cells (Fig. 3C). Of note, in EHMT2$^{−/−}$ cells, UNC0642-induced alteration in cell growth was substantially decreased although not completely eliminated (Fig. 3C). In the soft agar assay, we also observed that the deletion of EHMT2 partially blocked UNC0642-induced colony formation reduction in Hep3B cells (Fig. 3D). These findings suggested that UNC0642 suppresses the growth of HCC cells in an EHMT2-dependent manner in vitro. Moreover, in Hep3B and Huh1 xenograft assay, UNC0642 treatment on animals led to a prominent tumor growth inhibition (Fig. 3E and Additional file 1: Figure S3A). These effects of UNC0642 were strikingly eliminated by the loss function of EHMT2 (Fig. 3E and Additional file 1: Figure S3A). Collectively, UNC0642 exhibits anti-tumorigenesis effects in HCC both in vitro and in vivo by mainly targeting EHMT2.
Fig. 2 (See legend on previous page.)
Elevation of EHMT2 promotes Wnt/β-catenin pathway activity

Previously, Zhang et al. reported that the overexpression of EHMT2 in non-small cell lung cancer tissues epigenetically silenced tumor suppressor gene APC2 to activate the Wnt–β-catenin signaling pathway, and EHMT2 inhibitor UNC0638 suppressed tumor growth [23]. In another line, UNC0642 treatment decreased the levels of histone H3K9me2 and Ki67 expression and increased apoptosis in T24 and J82 cells (bladder cancer cells) [31]. In our experiments, we also found that β-catenin mainly localized in the nucleus (the activated form) both in Hep3B and Huh1 cells, and was expelled to the cytoplasm after deletion of EHMT2 (Fig. 4A). These observations imply that EHMT2 is a maintainer of Wnt–β-catenin signaling activation in HCC cells. Therefore, we estimated Wnt–β-catenin signaling activity in cells with/without EHMT2 using TOP/FOP luciferase reporter, a widely used Wnt–β-catenin activity indicator system. Intriguingly, our results showed that, in Hep3B and Huh1 cells, Wnt–β-catenin activity (after Wnt3a conditional medium treatment) of three independent EHMT2−/− single clones were substantially repressed when compared with that of wild type cells (Fig. 4B). Meanwhile, we observed that UNC0642 treatment efficiently suppressed Wnt3a-induced Wnt–β-catenin signaling activation both in wild-type Hep3B and Huh1 cells (Fig. 4C). Furthermore, our results revealed that around 61.8% of the effects of UNC0642 treatment were abolished by the deletion of EHMT2 in Huh1 cells (Fig. 4C), suggesting UNC0642 treatment efficiently suppressed Wnt–β-catenin pathway activity mainly mediated by EHMT2. Consistently, the expression (in mRNA level) of Wnt–β-catenin pathway target genes including Myc, CCND1, MMP-7, etc. were suppressed by UNC0642 treatment on cells cultured in 25% Wnt3a conditional medium, which also was largely abolished by deletion of EHMT2 in Hep3B cells (Fig. 4D). Also, the deletion of EHMT2 obviously abrogated UNC0642-induced reduction of total and nuclear β-catenin protein level in Hep3B cultured in 25% Wnt3a conditional medium (Fig. 4E). Collectively, the elevation of EHMT2 expression promotes Wnt–β-catenin pathway activity in different HCC cell lines.

EHMT2 directly binds to the APC promoter to suppress its expression

To investigate the mechanism by which EHMT2 regulates Wnt–β-catenin signaling activity, we analyzed the ChIP-seq data using EHMT2 antibody in HepG2 cells from (Encyclopedia of DNA Elements) ENCODE database to identify its putative target genes. Intriguingly, a wide EHMT2 bind peak was found around the promoter region of APC, a tumor suppressor that promotes the rapid degradation of β-catenin to negatively regulate Wnt–β-catenin signaling (Fig. 5A, circled by a red rectangle). Therefore, we designed primers that specifically bind around the EHMT2 bind peak to carry out ChIP-PCR to confirm these observations. As shown in Fig. 5B, our results indeed displayed that EHMT2 is specifically bound to APC's promoter both in Hep3B and Huh1 cells (Fig. 5B). To demonstrate the EHMT2 reaches APC’s promoter to execute functions, we treated cells with UNC0642 and then detected the H3K9me2 level of the promoter by ChIP-PCR assay. Our data showed that the APC promoter’s H3K9me2 level was reduced after UNC0642 treatment (Fig. 5C). Moreover, we found that, in Hep3B and Huh1 cells, the binding of polymerase II (PolII) on APC's promoter was slightly but significantly enhanced by UNC0642 treatment (Fig. 5D). All the lines of cues suggest that EHMT2 functionally binds to APC's promoter. More direct evidence indicated that UNC0642 treatment dramatically up-regulated APC mRNA level, which was largely abrogated by deletion of EHTM2 in Hep3B and Huh1 cells (Fig. 5E). Besides, APC protein levels also were induced by UNC0642 treatment in a dose-dependent manner (Fig. 5F). Taken together, our data demonstrate that EHMT2 directly binds to the
**Fig. 3** (See legend on previous page.)
APC promoter to suppress its expression by mediating H3K9me2.

APC mediates EHMT2’s oncogenic functions in HCC

It was well documented that APC involves the pathogenesis of various cancers including colorectal cancers, pancreatic duct adenocarcinoma, oral cancers, breast cancers [38–41]. To explore its possible association between EHMT2 and APC in HCC, we stably transfected APC into Hep3B and Huh1 cells using a lentivirus vector. In the Ki67 staining assay, we found that the inhibitory effects of UNC0642 on cell proliferation were significantly weakened by overexpression of APC, indicated by the UNC0642-induced reduction of Ki67+ percentage was obviously decreased in APC-overexpressed Hep3B and Huh1 cells when compared with wild type ones (Fig. 6A). Consistently, the growth curve by MTT assay also showed that the UNC0642-induced cell growth suppression was substantially alleviated in APC-overexpressed Hep3B and Huh1 cells (Fig. 6B). Furthermore, in the soft agar assay, we observed that UNC0642-induced inhibition of tumorsphere formation was partially relieved in APC-overexpressed Hep3B and Huh1 cells (Fig. 6C). These observations indicate that the oncogenic effects of EHMT2 largely are medicated by APC in vitro. We also carried out a xenograft assay using APC-overexpressed Hep3B and Huh1 cells to investigate the association between EHMT2 and APC in tumor growth in vivo. We found that UNC0642 treatment significantly suppressed tumor growth both in Hep3B and Huh1 cells (Fig. 6D and Additional file 1: Figure S4A). These effects were largely reversed by overexpression of APC in cells, shown by the UNC0642-induced difference in tumor growth were observed at the 7th week in the overexpression group instead of the 4th week in the control group (Fig. 6D and Additional file 1: Figure S4A). Likely, the final tumor weights of xenograft assay also displayed consistent results with tumor growth curve both in APC-overexpressed Hep3B and Huh1 cells (Fig. 6E, and Additional file 1: Figure S6B). Our observations collectively evidence that APC largely mediates EHMT2’s oncogenic functions in HCC both in vitro and in vivo.

Discussion

Previously, alteration of EHMT2 expression has been frequently observed in various human cancer types such as ovarian cancer, melanoma, esophageal squamous cell carcinoma, aggressive lung cancer, brain cancer [25, 28, 42]. For instance, in primary melanoma, higher expression of EHMT2 also was found when compared to normal skin samples, and knocking down its expression via small interfering RNA significantly reduces cell viability, migration, and invasion in human M14 and A375 melanoma cell lines in vitro [36]. In our study, we observed that EHMT2 expression in liver tumors was significantly 4–5 folds higher than their adjacent normal tissues both in mRNA and protein levels. Moreover, the high EHMT2 expression was unfavorable for the prognosis outcome of HCC patients in overall and disease-free survival. In three different HCC subtypes proposed by Chaisaingmongkol et al., EHMT2 expression (in mRNA level) still exhibited considerable discrimination (with HR > 2.1) in the overall survival of patients with HCC. Furthermore, we knocked out EHMT2 expression using CRISPR/Cas9 in Hep3B and Huh1 cells and observed that the deletion of EHMT2 restrained cell proliferation in vitro and tumor growth in vivo. All the results mentioned above demonstrated that the up-regulation of EHMT2 in liver cancer is functional. In fact, Wei et al. previously reported that EHMT2 expression is upregulated in human HCC, and they considered that the alteration of EHMT2 expression is attributed to miR-1 [43]. We also determined miR-1 expression in specimens of HCC patients but failed to detect a significant difference in expression level between tumor and normal tissues (data not shown). These data indicated that the
Fig. 4 (See legend on previous page.)
Fig. 5 EHMT2 directly binds to the APC promoter to suppress its expression. A EHMT2 binding peak on the promoter of APC. Public ChIP-seq data using EHMT2 antibody in HepG2 cells are from the ENCODE database. The red rectangle indicates the binding signal peaks. B ChIP-PCR showed that EHMT2 directly binds to the APC promoter. 1.0 × 10^7 Hep3B or Huh1 cells were subjected to ChIP using the EHMT2 antibody (RLP30 serves as negative control). n = 4 (mean ± SD); n.s, no significance and ***p < 0.001 by student’s t-test. C ChIP-PCR showed that the H3K9me2 level of APC promoter. Hep3B or Huh1 in 2B was treated with UNC0642 at a dose of 5.0 μM for 24 h, and then 1.0 × 10^7 cells were subjected to ChIP using the H3K9me2 antibody (IgG control is GFP antibody). n = 4 (mean ± SD); n.s, no significance and ***p < 0.001 by student’s t-test. D ChIP-PCR showed that PolII directly binds the APC promoter in Hep3B or Huh1 cells. Cells and treatment were the same as 5C. 1.0 × 10^7 cells were subjected to ChIP using the PolII antibody (IgG control is GFP antibody). n = 4 (mean ± SD); n.s, no significance, *p < 0.05 and **p < 0.01 by student’s t-test. E RT-qPCR showed APC expression in Hep3B and Huh1 cells. Cells and treatment were the same as 5C. n = 6 (mean ± SD); ***p < 0.001 by student’s t-test. F The APC protein level in cells was determined by Western blot. Hep3B and Huh1 were treated with UNC0642 at the indicated concentrations. n = 6 (mean ± SD); ***p < 0.001 by one-way ANOVA.
mechanisms causing EHMT2 expression alteration are quite complex, which needs further investigation.

In mouse models of acute myeloid leukemia, Lehnertz et al. established EHMT2 as a selective regulator of fast proliferating myeloid progenitors, indicated by the evidence that loss of EHMT2 significantly delays disease progression and reduces leukemia stem cell frequency by interacting with the leukemogenic transcription factor HoxA9 [27]. However, HoxA9 expression is too low to be detected both in liver normal and tumor tissues (data not shown) in our experiment. Recently, Ma and co-workers presented evidence that the histone-lysine methyltransferase EHMT2 is up-regulated in human cholangiocarcinoma, which enhances cell growth and invasiveness by epigenetically silencing the Hippo pathway kinase large tumor suppressor 2 (LATS2) [44]. We also analyzed LATS2 expression using public data from TCGA, and unfortunately, no significant difference was observed in the mRNA level of LATS2. In 2017, Wei et al. identified EHMT2 as a frequently upregulated histone methyltransferase in patients with HCC, which contributes to epigenetic silencing of tumor suppressor gene RARRES3 [43]. Hu et al. reported that EHMT2 protein interacted with Snail2 and histone deacetylases (HDACs) to form a complex to suppress E-cadherin (a hallmark of epithelial-mesenchymal transition EMT) transcription in HCC [45]. In our study, we demonstrated that EHMT2 is implicated in the regulation of Wnt–β-catenin signaling pathway in HCC by several lines of evidence: (1) EHMT2 directly binds to the promoter of APC in HepG2, Hep3B and Huh1; (2) EHMT2 mediates H3K9me2 of APC promoter; (3) EHMT2 promotes the expression of APC both in mRNA and protein levels; (4) the functions of EHMT2 are largely abolished by deletion of APC in Hep3B and Huh1 cells. Therefore, we considered that EHMT2 is versatile in the pathogenesis of HCC.

Over the past decade, the anti-tumor effects of EHMT2 inhibitors have been extensively investigated by independent groups. In 2018, Zhang et al. reported that UNC0642, a selective EHMT2 inhibitor significantly inhibited tumor growth of A549, H1299, and H1975 cell lines [23]. Cao et al. found that UNC0642 exhibits excellent anticancer effects with low cytotoxicity against urinary bladder cancer cells including T24, J82, and 5637 both in vitro and in vivo [31]. Also, Dong et al. demonstrated that the UNC0642 decreased cell viability and increased apoptosis of melanoma cells including M14 and A375 cell lines with minimal cell toxicity and good in vivo pharmacokinetic characteristics [36]. In this study, our findings showed that UNC0642 treatment also inhibited the H3K9me2 level and suppressed cell proliferation in vitro and tumor growth in vivo in Hep3B and Huh1 cells. Moreover, all these observations were largely abolished by the deletion of EHMT2 from cells, suggesting UNC0642 achieves its anti-tumor effects in an EHMT2 dependent manner. Besides, we demonstrated that UNC0642 inhibits the Wnt–β-catenin signaling pathway by several lines of evidence: 1) UNC0642 decreases Wnt3a-induced TOP/FOP luciferase activity and the expression of Wnt–β-catenin signaling pathway including Myc, CCND1 and MMP-7; 2) UNC0642 reduces the H3K9me2 level of APC promoter; 3) UNC0642 treatment inhibits PolII binding to APC promoter; 4) overexpression of APC from cells largely abolished the effects of UNC0642 treatment. In another line, UNC0642 is also an inhibitor of EHMT1, a homolog of EHMT2. In our experiment, we also observed that UNC0642 treatment is a little more powerful than deletion of EHMT2 on inhibiting cell proliferation, probably because UNC0642 treatment simultaneously suppresses the activity of EHMT1 and 2 in cells. Meanwhile, we noticed that the expression level of EHMT1 is around 1/3 of EHMT2 in mRNA, which also fails to alter in HCC tissues (data not shown). These observations suggest that EHMT2 rather than EHMT1 plays a dominant role in the pathogenesis of HCC. Altogether, we consider that UNC0642 possesses anti-tumor functions on HCC mainly by targeting EHMT2.

(See figure on next page.)

**Fig. 6** APC mediates EHMT2′s oncogenic functions in HCC. A Cell proliferation was determined by Ki67 staining. Hep3B and Huh1 cells were stably transfected with APC and treated with UNC0642 at a dose of 1.0 μM for 24 h. The nucleus of harvested cells was isolated. n = 6 (mean ± SD); *p < 0.05 and ***p < 0.001 by student’s t-test. B MTT assay determined the cell growth curve of Hep3B and Huh1 cells. Cells were treated with UNC0642 at a dose of 1.0 μM for 3 days. n = 6 (mean ± SD); *p < 0.05, **p < 0.01 and ***p < 0.001 by two-way ANOVA followed by post hoc Bonferroni multiple comparisons. C Soft agar assay determined the anchorage-independent growth ability of Hep3B and Huh1 cells. APC-overexpressed Hep3B and Huh1 cells were treated with UNC0642 at a dose of 1.0 μM with an interval of 3 days. n = 6 (mean ± SD); *p < 0.05 and ***p < 0.001 by student’s t-test. D Tumor growth curve of Hep3B xenograft assay. APC-overexpressed Hep3B cells in 6A were used. Animals were administered treated with UNC0642 at a dose of 1 mg/kg body weight via intraperitoneal with an interval of 3 days. n = 6 (mean ± SD); *p < 0.05, **p < 0.01 and ***p < 0.001 by two-way ANOVA followed by post hoc Bonferroni multiple comparisons. E Final tumor weight of Hep3B xenograft assay in 6D. The bottom picture is a representative of final tumors. n = 6 (mean ± SD); *p < 0.05 and ***p < 0.001 by student’s t-test. F A working model shows the roles of EHMT2 in the pathogenesis of HCC. β-cate, β-catenin
**Fig. 6** (See legend on previous page.)
Conclusion

In summary, we observed that the mRNA level of EHMT2 in HCC elevated significantly when compared with the normal controls of specimens from the public database and HCC patients we collected (Fig. 6F). The elevation of EHMT2 expression is required for HCC tumorigenesis and contributes to the activation of the Wnt–β-catenin pathway by epigenetically silencing APC expression (Fig. 6F). UNCO642 exhibits anti-tumorigenesis effects in HCC both in vitro and in vivo by targeting EHMT2 in Hep3B and Huh1 cells. Altogether, our observations emphasize that the EHMT2-APC axis is a contributor to Wnt–β-catenin pathway activation in HCC, and UNCO642 may be a potential candidate for target drug for HCC treatment.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13578-021-00663-9.

Additional file 1: Figure S1. High EHMT2 expression is unfavorable for patients with HCC. A, B EHMT2-based overall and disease-free survival analysis of patients with iClust1/2/3 HCC. In OS and DFS analysis, EHMT2 expression data from TCGA were used, and the median of EHMT2 expression served as the cutoff. High EHMT2, expression level more than median; Low EHMT2, expression level less than the median. A log-rank test was used for the hypothesis test. **p < 0.01 and ***p < 0.001 by two-way ANOVA followed by post hoc Bonferroni multiple comparisons. Figure S2. EHMT2 inhibitor exhibits anti-tumorigenesis effects in HCC. Tumor growth curve of Hep3B and Huh1 cells. Altogether, our observations emphasize that the EHMT2-APC axis is a contributor to Wnt–β-catenin pathway activation in HCC, and UNCO642 may be a potential candidate for target drug for HCC treatment.

Acknowledgements

Not applicable.

Authors’ contributions

YZ and QX designed the experiments. YG, YRZ, HL, YX and JZY performed the experiments. YZ performed particle tracking and analysis of experimental data. All contributed to the writing of the paper. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

ChIP-seq data using EHMT2 antibody are available in GSE170681 at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE170681 [doi:10.17989/ENCSR376FMN], reference number [PMID: 27528022].

Declarations

Ethics approval and consent to participate

All the protocols involved in our experiments were approved by the Ethics Committee of Qingdao University and study methodologies conformed to the standards set by the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing Interests

The authors declare no potential conflicts of interest.

Author details

1 Liver Disease Center, The Affiliated Hospital of Qingdao University, 59 Haier Blvd, Qingdao 266000, Shandong, China. 2 Organ Transplantation Center, The Affiliated Hospital of Qingdao University, 59 Haier Blvd, Qingdao 266000, Shandong, China. 3 Lead Contact, The Affiliated Hospital of Qingdao University, 59 Haier Blvd, Qingdao 266000, Shandong, China.

Received: 26 November 2020   Accepted: 22 July 2021

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–104.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, et al. Hepatocellular carcinoma management: an increasingly common problem. Proceedings. 2008:21:266–80.
4. Fomer A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.
5. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477–91.e1.
6. Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer. 2015;136:1921–30.
7. Li D, Li D, Song G, Liang D, Chen C, Zhang Y, et al. Cancer survival in China, 2003–2013: a population-based study. Cancer Med. 2018;7:1537–45.
8. Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 2018;412:283–8.
9. Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int. 2019;19:138.
10. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
11. Gebhardt R, Hovhannisyan A. Organ patterning in the adult stage: The role of Wnt/B-catenin signaling in liver zonation and beyond. Dev Dyn. 2009.
12. Li N, Wei L, Liu X, Bai H, Ye Y, Li D, et al. A frizzled-like cysteine-rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70:1231–45.
13. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 2000;289:1194–7.
14. Pez F, Lopez A, Kim M, Wands JR, Caron De Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59:1107–17.
15. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61.
16. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92:136–45.
17. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18:4997–5007.

18. Laurent-Pigué P, Legoux P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763–73.

19. Guichard C, Arnaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694–8.

20. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, et al. Mutations of beta-catenin and AXIN1 genes are a late event in human hepatocellular carcinoma. Liver Int. 2005;25:70–6.

21. Collins R, Cheng X. A case study in cross-talk: the histone lysine methyltransferases G9a and GLP methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2001;276:1779–91.

22. Casciello F, Windloch K, Gannon F, Lee JS. Functional Role of G9a Histone Methyltransferase in Cancer. Front Immunol. 2015;6:487.

23. Zhang K, Wang J, Yang L, Yuan YC, Tong TR, Wu J, et al. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HIP1alpha and APC2 gene expression in non-small cell lung cancer. Mol Cancer. 2018;17:153.

24. Tachibana M, Su L, Miller M, Liu F, Yi L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 2014;28:317–27.

25. Hua KT, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, et al. The H3K9 methyltransferase G9a plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16:1779–91.

26. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science. 2013;341:1451–6.

27. Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 2014;28:317–27.

28. Hua KT, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 2014;13:189.

29. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2007;26:77–90.

30. Huang J, Dorsey J, Chukov S, Perez-Burgos L, Zhang X, Jennewein T, et al. G9A and GLP methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010;285:9636–41.

31. Cao YP, Sun JY, Li MQ, Dong Y, Zhang YH, Yan J, et al. Inhibition of G9A by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. Acta Pharmacol Sin. 2019;40:1076–84.

32. Mitra AK, Davis DA, Tomar S, Roy L, Gurur H, Xie J, et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol. 2015;138:572–7.

33. Chaisangmongkol J, Budhu A, Dang H, Rababhdhada S, Pupadit B, Kwon SM, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:57–70.

34. Liang J, Bargon JE, Yeo CJ, Hong W, Zhang XD, Diao D, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013;56:8931–42.

35. Bellamy J, Szeres M, Meleghi Z, Dallolosso A, Kollareddy M, Catchpoole D, et al. Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified neuroblastoma. Front Oncol. 2020;10:818.

36. Pangenti R, Yang L, Zhang K, Wang J, Li W, Guo C, et al. G9a regulates tumorigenesis and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer. Clin Epigenetics. 2020;12:88.

37. Zhang L, Shao JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109:88.

38. Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111–23.

39. Ali J, Sabiba B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2020;10:980–97.

40. Wei L, Chiu DK, Tsang FH, Law CT, Cheng CL, Au SL, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2015;63:694–8.

41. Ma W, Han C, Zhang J, Song K, Chen W, Kwon H, et al. The histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2015;63:694–8.

42. Kato S, Weng QY, Insco ML, Chen KY, Muralidhar S, Pozniak J, et al. Gain-of-function genetic alterations of g9a drive oncogenesis. Cancer Discov. 2020;10:980–97.

43. Wei L, Chiu DK, Tsang FH, Law CT, Cheng CL, Au SL, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2015;63:694–8.

44. Wei L, Chiu DK, Tsang FH, Law CT, Cheng CL, Au SL, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2015;63:694–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.